These results suggest that, if a small molecule inhibitor of the K15-PLCγ1 interaction could be developed, it might be used to interfere with KSHV early gene expression and thereby its role in the pathogenesis of Kaposi’s Sarcoma. This evidence concerns the gene KRT15 and Kaposi's sarcoma.